Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for allegedly misleading investors regarding its financial health and operations during the period from February 27, 2023, to November 4, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Perrigo made materially false and misleading statements about its infant formula business acquired from Nestlé, which suffered from significant underinvestment and required substantial capital expenditures [5]. - It is alleged that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow [5]. - The lawsuit asserts that the positive statements made by Perrigo regarding its business and prospects were materially misleading and lacked a reasonable basis [5]. Group 2: Investor Information - Investors who purchased Perrigo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm for more information [3][6]. - A lead plaintiff must be appointed by January 16, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Perrigo Company plc regarding a class action lawsuit due to alleged misleading statements and operational deficiencies related to the company's infant formula business [1][3]. Summary by Sections Allegations - The complaint alleges that during the class period from February 27, 2023, to November 4, 2025, Perrigo made materially false and misleading statements, failing to disclose significant issues in its infant formula business acquired from Nestlé, including: - Underinvestment in maintenance and operational improvements [3] - Need for substantial capital and operational expenditures beyond stated cost estimates [3] - Significant manufacturing deficiencies in the infant formula facility [3] - Overstated financial results, including earnings and cash flow [3] - Misleading positive statements about the company's business and prospects [3] Class Action Details - The deadline for shareholders to register for the class action is January 16, 2026, and there is no cost or obligation to participate [4]. - Shareholders who register will be enrolled in a portfolio monitoring software for status updates throughout the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for violations of federal securities laws, alleging misleading statements and undisclosed issues related to its infant formula business [1][2]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased Perrigo securities between February 27, 2023, and November 4, 2025 [1]. - The complaint alleges that Perrigo and certain officers made false statements and failed to disclose significant operational issues in the infant formula business acquired from Nestlé [2]. Allegations Against Perrigo - Key allegations include: 1. Significant underinvestment in maintenance and operational improvements in the infant formula business [2]. 2. The need for substantial capital and operational expenditures beyond stated cost estimates to remediate the business [2]. 3. Manufacturing deficiencies in the infant formula facility [2]. 4. Overstated financial results, including earnings and cash flow, due to the aforementioned issues [2]. 5. Misleading positive statements regarding the Company's business and prospects [2]. Impact on Investors - Following the revelation of these issues, Perrigo's stock experienced a significant decline, resulting in financial losses for investors [3]. - Investors who suffered losses exceeding $150,000 are encouraged to participate in the lawsuit [3].

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Perrigo Company plc (NYSE: PRGO). CLASS PERIOD: February 27, 2023 to November 4, 2025 Shareholders who purchased shares of PRGO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/sec ...

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its infant formula business and financial performance during the specified class period [1][4]. Company Overview - Perrigo provides over-the-counter health and wellness solutions and acquired Nestlé's Gateway infant formula plant and the rights to Nestlé's Good Start® infant formula brand for $170 million in November 2022 [3]. Allegations of the Lawsuit - The lawsuit alleges that Perrigo made false or misleading statements and failed to disclose significant issues, including: - Underinvestment in the acquired infant formula business [4]. - The need for substantial capital and operational expenditures beyond stated estimates for remediation [4]. - Significant manufacturing deficiencies in the infant formula facility [4]. - Overstated financial results, including earnings and cash flow [4]. Financial Disclosures and Impact - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation, along with a 50% decline in earnings per share compared to the previous year, leading to a stock price drop of over 15% [5]. - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, and a gross margin decline of 90 basis points, resulting in a nearly 10% drop in stock price [6]. - On August 6, 2025, Perrigo's adjusted gross profit decreased by $30 million (6.9%), with a reported gross margin of 34.4%, causing a stock price decline of more than 11% [7]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business, slashing its fiscal year 2025 outlook, which included a negative sales growth guidance of -2.5% to -3% and a significant cut in expected earnings per share, leading to a stock price drop of over 25% [8].

Core Insights - Biotech and healthcare stocks experienced significant movements in after-hours trading, driven by corporate updates and investor anticipation [1] Company Updates - Butterfly Network, Inc. (BFLY) shares increased by 6.04% to $2.81 after a 14.22% rise to $2.65 at market close, following the announcement of CEO Joseph DeVivo and Interim CFO Megan Carlson's participation in the 8th Annual Evercore Healthcare Conference [2] - Citius Pharmaceuticals Inc. (CTXR) saw a 7.90% increase to $1.23 after a 15.15% rally to $1.14, attributed to a deeper collaboration with Verix for the commercialization of LYMPHIR, an FDA-approved immunotherapy expected to launch in Q4 2025 [3] - ProQR Therapeutics N.V. (PRQR) rose 6.80% to $2.20 after a flat close at $2.06, with no specific news indicating that the movement may be due to investor sentiment [4] - Perrigo Company plc (PRGO) advanced 3.97% to $13.14, building on a 3.10% gain at the close, reflecting steady investor interest despite no new announcements [4] - Tempest Therapeutics, Inc. (TPST) added 4.86% to $3.67 after reversing a decline, following the announcement of plans to acquire CAR-T programs from Factor Bioscience, expected to close in early 2026 [5] - Iterum Therapeutics plc (ITRM) rose 2.77% to $0.3969 after a 4.38% gain at the close, with no new updates released [6] - Processa Pharmaceuticals, Inc. (PCSA) edged up 1.86% to $0.26 despite a steep decline at the close, with no news issued [6]

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for allegedly misleading investors regarding its financial health and operations, particularly concerning its infant formula business acquired from Nestlé [2][6]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2023, and November 4, 2025, and investors must act by January 16, 2026, to serve as lead plaintiffs [2][4]. - Allegations include that Perrigo made materially false statements and failed to disclose significant underinvestment and manufacturing deficiencies in its infant formula business, leading to overstated financial results [6]. Group 2: Investor Guidance - Investors who purchased Perrigo securities during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5].

Core Viewpoint - Perrigo Company plc is facing a class action lawsuit for securities fraud due to alleged false and misleading statements regarding its baby formula business acquired from Nestlé, which suffered from underinvestment and required significant additional expenditures to address operational issues [5]. Summary by Sections Class Action Lawsuit - The Schall Law Firm is reminding investors of a class action lawsuit against Perrigo for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Perrigo's securities between February 27, 2025, and November 4, 2025, are encouraged to contact the firm before January 16, 2026 [2]. Allegations Against Perrigo - The complaint alleges that Perrigo made false and misleading statements to the market regarding the state of its baby formula business, which required substantial investments beyond initial cost estimates to rectify its issues [5]. - The company's public statements were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [5]. Legal Representation - The Schall Law Firm specializes in securities class action lawsuits and is representing investors globally [6].

Core Viewpoint - Perrigo Company plc is facing a class action lawsuit due to alleged securities fraud related to its infant formula business, which has experienced significant operational challenges and financial underperformance since its acquisition of Nestlé's Gateway infant formula plant [11]. Group 1: Acquisition and Financial Performance - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start brand for $170 million [3]. - The company reported fiscal year 2023 earnings on February 27, 2024, indicating a 50% decline in earnings per share compared to the previous year, attributed to remediation costs in the infant formula business [4]. - Following the earnings report, Perrigo's share price dropped by $4.87, or 15.14%, closing at $27.30 on February 27, 2024 [5]. Group 2: Ongoing Challenges and Market Reactions - On May 7, 2024, Perrigo reported a 34.5% decrease in net sales to $91 million for the first quarter, alongside a decline in gross margin [6]. - The share price fell by $3.28, or 9.8%, to close at $30.15 on May 7, 2024, following this announcement [7]. - On August 6, 2025, Perrigo disclosed that production issues led to scrapping approximately $11 million of inventory, resulting in a share price drop of $3.01, or 11.31%, to close at $23.61 [8]. Group 3: Strategic Review and Outlook Adjustments - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and revised its fiscal year 2025 outlook, cutting net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The expected adjusted diluted earnings per share was also reduced to a range of $2.70 to $2.80, down from $2.90 to $3.10, indicating a significant cut in growth expectations [9]. - Following this news, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on November 5, 2025 [10]. Group 4: Lawsuit Details - The class action lawsuit alleges that Perrigo made materially false and misleading statements regarding its business operations and failed to disclose significant issues within the acquired infant formula business [11]. - Specific allegations include underinvestment in maintenance and operational improvements, the need for substantial capital expenditures for remediation, and overstated financial results [11]. - Investors who purchased Perrigo securities during the class period are encouraged to participate in the lawsuit, with a deadline to file a lead plaintiff motion by January 16, 2026 [12].

Core Viewpoint - Class action lawsuits have been filed against multiple publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and prospects, leading to investor losses. Group 1: Stride, Inc. (NYSE: LRN) - The class period for Stride, Inc. is from October 22, 2024, to October 28, 2025, with a lead plaintiff deadline of January 12, 2026 [2] - Allegations include inflating enrollment numbers by retaining "ghost students," cutting staffing costs by overloading teachers, ignoring compliance requirements, suppressing whistleblowers, and losing student enrollments [2] Group 2: Primo Brands Corporation (NYSE: PRMB) - The class period for Primo Brands Corporation is from June 17, 2024, to November 6, 2025, with a lead plaintiff deadline of January 12, 2026 [3] - Allegations include poor merger integration with BlueTriton Brands, major supply disruptions affecting customers, and misleading positive statements about the company's business [3] Group 3: Freeport-McMoran Inc. (NYSE: FCX) - The class period for Freeport-McMoran Inc. is from February 15, 2022, to September 24, 2025, with a lead plaintiff deadline of January 12, 2026 [4] - Allegations include inadequate safety measures at the Grasberg Block Cave mine, which posed risks to workers and led to regulatory and reputational risks, along with misleading positive statements about the company's operations [4] Group 4: Perrigo Company plc (NYSE: PRGO) - The class period for Perrigo Company plc is from February 27, 2023, to November 4, 2025, with a lead plaintiff deadline of January 16, 2026 [6] - Allegations include significant underinvestment in the infant formula business acquired from Nestlé, the need for substantial capital expenditures for remediation, and overstated financial results due to manufacturing deficiencies [6]